L
Lillian Tran
Researcher at National Institutes of Health
Publications - 6
Citations - 1541
Lillian Tran is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Internal medicine & Antibody. The author has an hindex of 4, co-authored 4 publications receiving 1367 citations.
Papers
More filters
Journal ArticleDOI
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Hua-Xin Liao,Rebecca M. Lynch,Tongqing Zhou,Feng Gao,Feng Gao,S. Munir Alam,S. Munir Alam,Scott D. Boyd,Andrew Fire,Krishna M. Roskin,Chaim A. Schramm,Zhenhai Zhang,Jiang Zhu,Lawrence Shapiro,Lawrence Shapiro,Nisc Comparative Sequencing Program,James C. Mullikin,Sandrasegaram Gnanakaran,Peter T. Hraber,Kevin Wiehe,Kevin Wiehe,Garnett Kelsoe,Garnett Kelsoe,Guang Yang,Guang Yang,Shi-Mao Xia,Shi-Mao Xia,David C. Montefiori,David C. Montefiori,Robert Parks,Robert Parks,Krissey E. Lloyd,Krissey E. Lloyd,Richard M. Scearce,Richard M. Scearce,Kelly A. Soderberg,Kelly A. Soderberg,Myron S. Cohen,Gift Kamanga,Mark K. Louder,Lillian Tran,Yue Chen,Yue Chen,Fangping Cai,Fangping Cai,Sheri Chen,Sheri Chen,Stephanie Moquin,Xiulian Du,M. Gordon Joyce,Sanjay Srivatsan,Baoshan Zhang,Anqi Zheng,George M. Shaw,Beatrice H. Hahn,Thomas B. Kepler,Bette T. Korber,Peter D. Kwong,John R. Mascola,Barton F. Haynes,Barton F. Haynes +60 more
TL;DR: The isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection and its co-crystal structure revealed a new loop-based mechanism of CD4-binding-site recognition.
Journal ArticleDOI
Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors
Tongqing Zhou,Rebecca M. Lynch,Lei Chen,Priyamvada Acharya,Xueling Wu,Nicole A. Doria-Rose,M. Gordon Joyce,Daniel Lingwood,Cinque Soto,Robert T. Bailer,Michael J. Ernandes,Rui Kong,Nancy S. Longo,Mark K. Louder,Krisha McKee,Sijy O'Dell,Stephen D. Schmidt,Lillian Tran,Zhongjia Yang,Aliaksandr Druz,Timothy S. Luongo,Stephanie Moquin,Sanjay Srivatsan,Yongping Yang,Baoshan Zhang,Anqi Zheng,Marie Pancera,Tatsiana Kirys,Ivelin S. Georgiev,Tatyana Gindin,Hung-Pin Peng,An-Suei Yang,James C. Mullikin,Matthew D. Gray,Leonidas Stamatatos,Dennis R. Burton,Dennis R. Burton,Wayne C. Koff,Myron S. Cohen,Barton F. Haynes,Joseph P. Casazza,Mark Connors,Davide Corti,Antonio Lanzavecchia,Quentin J. Sattentau,Robin A. Weiss,Anthony P. West,Pamela J. Bjorkman,Johannes F. Scheid,Michel C. Nussenzweig,Michel C. Nussenzweig,Lawrence Shapiro,Lawrence Shapiro,John R. Mascola,Peter D. Kwong +54 more
TL;DR: The repertoire for effective recognition of the CD4 supersite thus comprises antibodies with distinct paratopes arrayed about two optimal geometric orientations, one achieved by CDR H3 ontogenies and the other achieved by VH-gene-restricted ontogeny.
Journal ArticleDOI
The development of CD4 binding site antibodies during HIV-1 infection.
Rebecca M. Lynch,Lillian Tran,Mark K. Louder,Stephen D. Schmidt,Myron S. Cohen,Rebecca DerSimonian,Zelda Euler,Elin S. Gray,Salim S. Abdool Karim,Jennifer L. Kirchherr,David C. Montefiori,Sengeziwe Sibeko,Kelly A. Soderberg,Georgia D. Tomaras,Zhi Yong Yang,Gary J. Nabel,Hanneke Schuitemaker,Lynn Morris,Barton F. Haynes,John R. Mascola +19 more
TL;DR: Improved understanding of the immunological factors associated with the development and maturation of neutralizing CD4bs antibodies during HIV-1 infection may provide insights into the requirements for eliciting this response by vaccination.
Journal ArticleDOI
HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies
Rebecca M. Lynch,Patrick Wong,Lillian Tran,Sijy O'Dell,Martha Nason,Yuxing Li,Xueling Wu,John R. Mascola +7 more
TL;DR: It is shown that escape from VRC01 class antibodies can be associated with impaired viral entry and replication; however, during the course of natural infection, compensatory mutations restore the ability of the virus to replicate normally.
Posted ContentDOI
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Katrin Hager,Gonzalo Pérez Marc,Philipe Gobeil,Raúl² Silva Díaz,Gretchen M. Heizer,Conrado J. Llapur,Alexander I. Makarkov,E. Vasconcellos,Stéphane Pillet,F Riera,K. Bhutada,Patrice Wolff,Greg Wallace,H.A. Aazami,Caroline E. Jones,Fernando P. Polack,J. D. Atkins,Iohann Boulay,Jiwanjeet Dhaliwall,Nathalie Charland,Michele Couture,J. Jiang-Wright,Nathalie Landry,S. Lapointe,Aurélien Lorin,Asif Mahmood,Lawrence H. Moulton,Emmy Pahmer,Jason Parent,P. Saxena,Annie Séguin,Lillian Tran,Thomas Breuer,Maria Angeles Ceregido,Marguerite Koutsoukos,François Roman,J. Namba,Marc-André D'Aoust,Sonia Trépanier,Yoshiaki Kimura,The CoVLP Study Team,Brian J. Ward +41 more
TL;DR: The primary efficacy endpoint was prevention of symptomatic SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of [≥]160 virologically-confirmed cases, and tolerability and safety of CoVLP+AS03 were also determined.